Los Angeles—Are oral agents or biologics more effective for plaque psoriasis in the short- and long-term? A new study sought to answer that question.
A report in JAMA Dermatology notes that while clinical benefits of novel treatments in severe psoriasis are well-established, patient response is not always consistent. Acknowledging the absence of head-to-head randomized trials, University of Southern California–led researchers conducted a meta-analysis synthesizing data from multiple studies to assess comparative efficacy among psoriasis treatments.
Based on 60 clinical trials for short-term efficacy, they conclude that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest Psoriasis Area and Severity Index response rates at 10 to 16 weeks from baseline. The meta-analysis of long-term efficacy, meanwhile, suggests that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest response rates at 44 to 60 weeks.
The systematic literature reviews were conducted on December 4, 2017, and updated on September 17, 2018, using the Embase, MEDLINE, and Cochrane Central Register databases. Included were phase II, III, or IV randomized clinical trials of treatments licensed by the FDA and the European Medicines Agency for adults with moderate-to-severe psoriasis. The focus was on records with data on Psoriasis Area and Severity Index (PASI) assessment of 75%, 90%, and 100% reductions (PASI 75, 90, and 100) at 10 to 16 weeks (short-term efficacy) or 44 to 60 weeks (long-term efficacy) from baseline.
“This study provides an assessment of the comparative efficacy among treatments for moderate to severe plaque psoriasis,” the authors conclude. “The meta-analysis suggests that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were associated with the highest PASI response rates in both short-term and long-term therapy.”
The meta-analyses are important because treatment options for patients with moderate-to-severe psoriasis have expanded so much over the past decade. Biologics provide targeted inhibition of immune-mediated pathways involving specific cytokines, such as tumor necrosis factor (TNF), interleukin (IL)-17, and IL-23.
“Although the increased options of biologics and oral treatments for moderate to severe psoriasis have provided substantial benefit to patients, it can be challenging for clinicians to determine how the medications compare with one another. Variations exist across different therapies with regard to efficacy, safety, and dosing profiles,” the researchers point out.
« Click here to return to Weekly News Update.
A report in JAMA Dermatology notes that while clinical benefits of novel treatments in severe psoriasis are well-established, patient response is not always consistent. Acknowledging the absence of head-to-head randomized trials, University of Southern California–led researchers conducted a meta-analysis synthesizing data from multiple studies to assess comparative efficacy among psoriasis treatments.
Based on 60 clinical trials for short-term efficacy, they conclude that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest Psoriasis Area and Severity Index response rates at 10 to 16 weeks from baseline. The meta-analysis of long-term efficacy, meanwhile, suggests that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest response rates at 44 to 60 weeks.
The systematic literature reviews were conducted on December 4, 2017, and updated on September 17, 2018, using the Embase, MEDLINE, and Cochrane Central Register databases. Included were phase II, III, or IV randomized clinical trials of treatments licensed by the FDA and the European Medicines Agency for adults with moderate-to-severe psoriasis. The focus was on records with data on Psoriasis Area and Severity Index (PASI) assessment of 75%, 90%, and 100% reductions (PASI 75, 90, and 100) at 10 to 16 weeks (short-term efficacy) or 44 to 60 weeks (long-term efficacy) from baseline.
“This study provides an assessment of the comparative efficacy among treatments for moderate to severe plaque psoriasis,” the authors conclude. “The meta-analysis suggests that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were associated with the highest PASI response rates in both short-term and long-term therapy.”
The meta-analyses are important because treatment options for patients with moderate-to-severe psoriasis have expanded so much over the past decade. Biologics provide targeted inhibition of immune-mediated pathways involving specific cytokines, such as tumor necrosis factor (TNF), interleukin (IL)-17, and IL-23.
“Although the increased options of biologics and oral treatments for moderate to severe psoriasis have provided substantial benefit to patients, it can be challenging for clinicians to determine how the medications compare with one another. Variations exist across different therapies with regard to efficacy, safety, and dosing profiles,” the researchers point out.
« Click here to return to Weekly News Update.
